Sulfated glycosaminoglycans inhibit LCMV entry and modulate antiviral immunity and pathology

ABSTRACT: Viral infections remain a major challenge due to the limited availability and efficacy of current treatments. Existing antivirals primarily target viral replication but are often virus-specific and can lead to drug resistance. Sulfated glycosaminoglycans (GAGs) have emerged as promising broad-spectrum agents that block viral binding and entry into host cells. Here, we show that highly sulfated GAGs restrict the infectivity of both pathogenic and non-pathogenic Arenaviruses. Using the lymphocytic choriomeningitis virus (LCMV) model, we demonstrate that GAG exposure reduces viral entry and infection in cell lines and bone marrow-derived dendritic cells, impairing their ability to activate antiviral T cells. In vivo, early exposure of LCMV to dextran sulfate suppressed immune activation, lead

SUBMITTER: Michal Gorzkiewicz 

PROVIDER: S-SCDT-10_1038-S44321-026-00387-8 | biostudies-other |

REPOSITORIES: biostudies-other